Alzheimer disease (AD) is the sixth leading cause of death in the United States and is projected to affect over 13 million people by the year 2060. Although there is currently no cure for AD, ...

MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ('Annovis' or the 'Company'), a late-stage clinical ...

Annovis Bio (ANVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju ...

Researchers identify a key pathway leading to neurodegeneration in early stages of ALS, hinting at the potential for short-circuiting the progression of the fatal disease if diagnosed early.

Researchers have uncovered a mechanism that may trigger ALS’s earliest stages, identifying proteins that mislocalize, causing ...

"I am honored to join C-Path and to lead the CPAD Consortium in its mission to drive therapeutic innovation for Alzheimer's disease," said Dr. Tatton. "There is so much momentum in AD research today, ...